Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FORTRESS BIOTECH, INC.

(FBIO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
2.79(c) 2.85(c) 2.66(c) 2.65(c) 2.42(c) Last
479 548 320 027 557 798 458 405 933 143 Volume
-1.41% +2.15% -6.67% -0.38% -8.68% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 95,0 M - -
Net income 2021 -26,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,56x
Yield 2021 -
Sales 2022 119 M - -
Net income 2022 -9,19 M - -
Net Debt 2022 - - -
P/E ratio 2022 -37,8x
Yield 2022 -
Capitalization 241 M 241 M -
Capi. / Sales 2021 2,54x
Capi. / Sales 2022 2,02x
Nbr of Employees 111
Free-Float 70,2%
More Financials
Company
Fortress Biotech, Inc. (Fortress) is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The... 
Sector
Pharmaceuticals
Calendar
03/21Earnings Release
More about the company
Ratings of Fortress Biotech, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about FORTRESS BIOTECH, INC.
11/29Journey Medical Corporation Introduces Expanded Board of Directors
AQ
11/18Avenue Therapeutics Announces Exercise and Closing of Underwriter's Over-Allotment Opti..
AQ
11/16Journey Medical Corporation Announces Closing of Initial Public Offering
GL
11/15FORTRESS BIOTECH : Reports Record Third Quarter 2021 Financial Results and Recent Corporat..
PU
11/15FORTRESS BIOTECH : Q3 Earnings Snapshot
AQ
11/15FORTRESS BIOTECH, INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/15Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 EPS $0.54
MT
11/15Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corpora..
GL
11/15Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q3 Revenue $21.1M
MT
11/15Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/12Journey Medical Corp. Prices IPO at $10 Per Share
MT
11/12Journey Medical Corporation Prices $35.2 Million Initial Public Offering
AQ
11/08Fortress Biotech's Journey Medical Launches Initial Public Offering for Nasdaq Listing
MT
11/08Journey Medical Corporation Announces Launch of its Initial Public Offering
GL
11/03InvaGen Pharmaceuticals Inc. (?InvaGen?) cancelled the acquisition of Avenue Therapeuti..
CI
More news
News in other languages on FORTRESS BIOTECH, INC.
11/15Earnings Flash (FBIO) FORTRESS BIOTECH annonce un chiffre d'affaires de 21,1 millions d..
11/12Journey Medical Corp. fait son entrée en bourse à 10 $ par action
10/14Fortress Biotech déclare que les études de base du CUTX-101 chez les patients atteints ..
09/29MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
09/29MÄRKTE USA/Moderate Erholung von Vortagesabsturz
More news
Analyst Recommendations on FORTRESS BIOTECH, INC.
More recommendations
Chart FORTRESS BIOTECH, INC.
Duration : Period :
Fortress Biotech, Inc. Technical Analysis Chart | FBIO | US34960Q1094 | MarketScreener
Technical analysis trends FORTRESS BIOTECH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,42 $
Average target price 7,60 $
Spread / Average Target 214%
EPS Revisions
Managers and Directors
Lindsay Allan Rosenwald Chairman, President & Chief Executive Officer
Robyn M. Hunter Chief Financial Officer, Secretary & Treasurer
Jimmie Harvey Independent Director
J. Jay Lobell Independent Director
Malcolm I. Hoenlein Independent Director
Sector and Competitors
1st jan.Capi. (M$)
FORTRESS BIOTECH, INC.-23.66%241
CSL LIMITED5.12%95 233
WUXI BIOLOGICS (CAYMAN) INC.0.39%56 209
SAMSUNG BIOLOGICS CO.,LTD.8.96%50 311
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%32 892